Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,886 questions in 74 reviews · Skin

current versions

No studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Topical foscarnet vs placebo Severity of attack of recurrent herpes labialis during use of the preventative intervention (duration of pain) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 113 participants	Moderate
Topical 1,5‐pentanediol vs placebo Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 102 participants	Moderate
Topical 1,5‐pentanediol vs placebo Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 102 participants	Moderate
Topical 1,5‐pentanediol vs placebo Severity (blistering, swelling, or pain) of recurrence · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 1.05 [0.91, 1.2]	1 study · 224 participants	Moderate
Oral aciclovir (short‐term) vs placebo Adverse effects during use of the preventative intervention ‐ aciclovir 800 mg twice daily · participants with recurrent herpes simplex labialis (cold sores on the lips) Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 0.98 [0.7, 1.38]	1 study · 239 participants	Moderate
Sunscreen vs placebo Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) ‐ solar radiation · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 1.12 [0.25, 5.06]	1 study · 51 participants	Low
Sunscreen vs placebo Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) ‐ experimental ultraviolet light · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 0.07 [0.01, 0.33]	2 studies · 111 participants	Very low
Sunscreen vs placebo Incidence of herpes labialis during use of the preventative intervention (by culture) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 73 participants	Very low
Interferon vs placebo Incidence of herpes labialis during use of the preventative intervention ‐ presurgical · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 1.59 [1.05, 2.41]	1 study · 32 participants	Low
Interferon vs placebo Incidence of herpes labialis during use of the preventative intervention ‐ postsurgical · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 0.99 [0.59, 1.66]	1 study · 44 participants	Low
Interferon vs placebo Incidence of herpes labialis during use of the preventative intervention ‐ pre‐ and postsurgical · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 0.57 [0.34, 0.95]	1 study · 37 participants	Low
Interferon vs placebo Adverse effects during use of the preventative intervention (fever) ‐ presurgical · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 2.45 [1.26, 4.78]	1 study · 32 participants	Moderate
Interferon vs placebo Adverse effects during use of the preventative intervention (fever) ‐ postsurgical · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 1.96 [1, 3.84]	1 study · 44 participants	Moderate
Interferon vs placebo Adverse effects during use of the preventative intervention (fever) ‐ pre‐ and postsurgical · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 11.76 [0.71, 195.11]	1 study · 38 participants	Moderate
Gamma globulin vs histamine (control) Duration of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 72 participants	Low
Oral aciclovir (short‐term) vs placebo Adverse effects during use of the preventative intervention ‐ aciclovir 400 mg twice daily · participants with recurrent herpes simplex labialis (cold sores on the lips) Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 2.3 [0.62, 8.58]	2 studies · 183 participants	Low
Gamma globulin vs histamine (control) Severity of attack of recurrent herpes labialis during use of the preventative intervention (less severe recurrences than usual) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 0.97 [0.74, 1.28]	1 study · 73 participants	Low
Thymopentin vs placebo Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 36 participants	Moderate
Thymopentin vs placebo Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 2 [0.42, 9.58]	1 study · 36 participants	Moderate
HSV vaccination vs placebo Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 64 participants	Moderate
HSV vaccination vs placebo Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 0.33 [0.01, 7.45]	1 study · 64 participants	Moderate
Yellow fever vaccination vs placebo Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 1 participants	Moderate
Yellow fever vaccination vs placebo Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	RR 0.33 [0.01, 7.45]	1 study · 24 participants	Moderate
Laser vs no interventions Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 71 participants	Very low
Laser vs no interventions Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	2 studies · 119 participants	Low
Hypnotherapy vs control Incidence of herpes labialis during use of the preventative intervention (change in frequency of recurrence) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 21 participants	Very low
Oral aciclovir (long‐term) vs placebo Incidence of herpes labialis during use of the preventative intervention (by culture) · participants with recurrent herpes simplex labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 40 participants	Low
Hypnotherapy vs control Severity of attack of recurrent herpes labialis during use of the preventative intervention (change in intensity) · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 21 participants	Very low
Hypnotherapy vs control Change in severity (pain) of herpes labialis · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 21 participants	Very low
Hypnotherapy vs control Change in severity (impairment of appearance) of herpes labialis · participants with recurrent herpes labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 21 participants	Very low
Oral aciclovir (long‐term) vs placebo Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) · participants with recurrent herpes simplex labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 40 participants	Low
Oral aciclovir (long‐term) vs placebo Duration of attack of herpes labialis during use of the preventative intervention · participants with recurrent herpes simplex labialis Interventions for prevention of herpes simplex labialis (cold sores on the lips) (2015) · Cochrane	no estimate extracted	1 study · 40 participants	Low
SLNB vs Observation Overall Survival Intention‐to‐treat Death from any cause during the study · patients with localised primary cutaneous melanoma Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma (2015) · Cochrane	HR 0.99 [0.82, 1.19]	1 study · 1661 participants	Low
SLNB vs Observation Surgical Morbidity (Within 30 d) Related to the Regional Nodal Basin in Patients Assigned to the 2 Treatment Arms of MSLT‐I Any complication in the dissected basin, regional or systemic related to the surgical treatment in the regional nodal basin · patients with localised primary cutaneous melanoma Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma (2015) · Cochrane	RR 14.36 [6.74, 30.59]	1 study · 1735 participants	Low
SLNB vs Observation Surgical Morbidity (Within 30 d) Related to Wide Excision of the Primary Site in Patients Assigned to the 2 Treatment Arms of MSLT‐I Any Surgical Complication related to the wide excision site · patients with localised primary cutaneous melanoma Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma (2015) · Cochrane	RR 1.11 [0.9, 1.37]	1 study · 1735 participants	Low
SLNB vs Observation Disease‐specific Survival Death from melanoma · patients with localised primary cutaneous melanoma Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma (2015) · Cochrane	HR 0.92 [0.74, 1.14]	1 study · 1661 participants	Low
SLNB vs Observation Disease‐free Survival First pathologically confirmed recurrence · patients with localised primary cutaneous melanoma Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma (2015) · Cochrane	HR 0.75 [0.63, 0.89]	1 study · 1661 participants	Low
SLNB vs Observation Rate of pathologically confirmed locoregional recurrence following SLNB and curative CLND First pathologically confirmed local and/or regional recurrence · patients with localised primary cutaneous melanoma Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma (2015) · Cochrane	RR 0.56 [0.45, 0.69]	1 study · 1661 participants	Low
SLNB vs Observation Rate of development of distant metastases following SLNB and curative CLND First pathologically confirmed distant metastasis · patients with localised primary cutaneous melanoma Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma (2015) · Cochrane	RR 1.33 [1.03, 1.72]	1 study · 1661 participants	Low
Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg Participant‐reported improvement of hirsutism ‐ not measured · patients with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane	no estimate extracted	NR	No studies
Flutamide 250 mg b.i.d. vs placebo Proportion of participants who reported an adverse event · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane	no estimate extracted	2 studies · 60 participants	Very low
Flutamide 250 mg b.i.d. vs placebo Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane	no estimate extracted	2 studies · 60 participants	Very low
Flutamide 250 mg b.i.d. vs placebo Change in serum androgen levels · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane	no estimate extracted	2 studies · 60 participants	Low
Flutamide 250 mg b.i.d. vs placebo Change in BMI kg/m² · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane	no estimate extracted	1 study · 40 participants	Very low
Flutamide 250 mg b.i.d. vs placebo Improvement of other clinical signs of hyperandrogenism Mean number of menses in previous 6 months Scale from: 0 to 6 · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane	no estimate extracted	1 study · 40 participants	Very low
Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane	RR 2 [0.88, 4.54]	1 study · 20 participants	Low
Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane	no estimate extracted	NR	No studies
Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg Proportion of participants who reported an adverse event · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane	no estimate extracted	2 studies · 40 participants	Low
Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane	no estimate extracted	2 studies · 40 participants	Very low
Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg Change in serum androgen levels · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane	no estimate extracted	2 studies · 40 participants	Moderate